McKesson to Acquire Precision Medicine Group for Approximately $2.25 Billion

McKesson announced on August 25, 2026, that it signed a definitive agreement to acquire Precision Medicine Group, LLC for approximately $2.25 billion.

Precision Medicine provides clinical research, biomarker intelligence, laboratory services, market-access consulting, and biopharma commercialization support.

McKesson said the acquisition will strengthen clinical-trial execution, expand its clinical-research capabilities, and broaden services for biopharmaceutical customers.

After closing, Precision Medicine will become part of McKesson’s Oncology & Multispecialty segment.

The transaction remains subject to customary closing conditions, including regulatory approvals. McKesson has not announced an expected closing date.

Reports indicate Precision Medicine is being acquired from Blackstone. The deal supports McKesson’s strategy of expanding beyond traditional drug distribution into higher-growth healthcare and pharmaceutical services.